Teleflex Inc. Adds Director Sean M. Salmon to Board

What Happened
Teleflex Incorporated (TFX) announced on September 8, 2026, that its Board increased from eight to nine directors and elected Sean M. Salmon to fill the new seat. Mr. Salmon, age 61, was also appointed to the Board’s Growth and Operating Committee. The company furnished a press release regarding the appointment the same day.

Key Details

• Election date: September 8, 2026; board size increased from eight to nine directors.
• New director: Sean M. Salmon; age 61; currently provides consulting services through Zamboni Holdings, LLC (founded December 2025).
• Prior experience: 21-year career at Medtronic plc with senior roles including Executive VP & President, Cardiovascular (Jan 2021–Sep 2025) and other leadership roles from 2004–2025; earlier roles at C.R. Bard and Johnson & Johnson.
• Compensation and disclosures: Mr. Salmon will receive the Company’s standard non‑employee director compensation (per Teleflex’s 2026 proxy, pp.15–17). No related‑party transactions or special arrangements were reported.
• Company action: Press release furnished as Exhibit 99.1 to the Form 8‑K.

Why It Matters
Adding an experienced medtech executive with deep cardiovascular and device industry experience may strengthen Teleflex’s board expertise in growth, product strategy and operations. For investors, this is a governance update (no financial statements or executive compensation changes disclosed beyond standard director pay) and signals the board’s focus on operational and growth oversight. The filing notes no related‑party issues, and compensation will follow the company’s published non‑employee director policy.